These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24152964)

  • 1. Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice.
    Suzuki O; Mizukami K; Etori M; Sogawa Y; Takagi N; Tsuchida H; Morimoto K; Goto T; Yoshino T; Mikkaichi T; Hirahara K; Nakamura S; Maeda H
    J Pharmacol Sci; 2013; 123(3):219-26. PubMed ID: 24152964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
    Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
    PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of phosphodiesterase 4B in IL-8/LTB4-induced human neutrophil chemotaxis evaluated with a phosphodiesterase 4B inhibitor.
    Suzuki O; Goto T; Yoshino T; Nakamura S; Maeda H
    Acta Pharm; 2015 Jun; 65(2):191-7. PubMed ID: 26011935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
    Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roflumilast (Daliresp) for COPD.
    Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
    [No Abstract]   [Full Text] [Related]  

  • 6. Roflumilast for severe COPD?
    Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.
    McDonough W; Aragon IV; Rich J; Murphy JM; Abou Saleh L; Boyd A; Koloteva A; Richter W
    FASEB J; 2020 Sep; 34(9):12533-12548. PubMed ID: 32738081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.
    Kubo S; Kobayashi M; Iwata M; Miyata K; Takahashi K; Shimizu Y
    Int Immunopharmacol; 2012 Jan; 12(1):59-63. PubMed ID: 22041526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roflumilast cream (Zoryve) for atopic dermatitis.
    Med Lett Drugs Ther; 2024 Sep; 66(1711):150-151. PubMed ID: 39250342
    [No Abstract]   [Full Text] [Related]  

  • 11. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast.
    Tao X; He H; Peng J; Xu R; Fu J; Hu Y; Li L; Yang X; Feng X; Zhang C; Zhang L; Yu X; Shen A; Huang K; Fu Q
    Pharmacol Res; 2022 Jan; 175():106004. PubMed ID: 34826603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.
    Rieder F; Siegmund B; Bundschuh DS; Lehr HA; Endres S; Eigler A
    PLoS One; 2013; 8(2):e56867. PubMed ID: 23468885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
    Rogliani P; Calzetta L; Cazzola M; Matera MG
    Expert Opin Drug Saf; 2016 Aug; 15(8):1133-46. PubMed ID: 27279341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.
    Timmer W; Leclerc V; Birraux G; Neuhäuser M; Hatzelmann A; Bethke T; Wurst W
    J Clin Pharmacol; 2002 Mar; 42(3):297-303. PubMed ID: 11865966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the role of roflumilast in chronic obstructive pulmonary disease?
    Lau C; Mehta AC; Hatipoglu U
    Cleve Clin J Med; 2017 Jan; 84(1):13-15. PubMed ID: 28084977
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
    Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE
    Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.
    Kobayashi M; Kubo S; Iwata M; Ohtsu Y; Takahashi K; Shimizu Y
    Int Immunopharmacol; 2011 Jun; 11(6):732-9. PubMed ID: 21315169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roflumilast: a selective phosphodiesterase 4 inhibitor.
    Christie P
    Drugs Today (Barc); 2005 Oct; 41(10):667-75. PubMed ID: 16389409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
    Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
    Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic options in the management of COPD - focus on roflumilast.
    Antoniu SA
    Int J Chron Obstruct Pulmon Dis; 2011; 6():147-55. PubMed ID: 21468165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.